{"id":138784,"date":"2022-06-15T11:20:51","date_gmt":"2022-06-15T11:20:51","guid":{"rendered":"https:\/\/stg.strategist1trial.com\/intrebari-frecvente\/"},"modified":"2025-09-18T20:14:13","modified_gmt":"2025-09-18T20:14:13","slug":"intrebari-frecvente","status":"publish","type":"page","link":"https:\/\/stg.strategist3trial.com\/ro\/intrebari-frecvente\/","title":{"rendered":"\u00centreb\u0103ri frecvente"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;100&#8243; back_color=&#8221;color-138503&#8243; back_image=&#8221;112255&#8243; back_repeat=&#8221;no-repeat&#8221; back_attachment=&#8221;scroll&#8221; back_position=&#8221;center center&#8221; parallax=&#8221;yes&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; enable_bottom_divider=&#8221;default&#8221; bottom_divider_inv=&#8221;tilt&#8221; shape_bottom_invert=&#8221;yes&#8221; shape_bottom_h_use_pixel=&#8221;&#8221; shape_bottom_height=&#8221;100&#8243; shape_bottom_color=&#8221;color-xsdn&#8221; shape_bottom_opacity=&#8221;100&#8243; shape_bottom_index=&#8221;0&#8243; medium_visibility=&#8221;yes&#8221; mobile_visibility=&#8221;yes&#8221; row_name=&#8221;iphone&#8221; el_class=&#8221;gradient&#8221; uncode_shortcode_id=&#8221;111541&#8243; back_color_type=&#8221;uncode-palette&#8221; shape_bottom_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;7&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; animation_delay=&#8221;200&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;276875&#8243; column_width_pixel=&#8221;1000&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; heading_semantic=&#8221;h1&#8243; text_font=&#8221;font-514338&#8243; text_weight=&#8221;300&#8243; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;140228&#8243; text_color_type=&#8221;uncode-palette&#8221;]<span style=\"font-weight: 400;\">\u00centreb\u0103ri frecvente<\/span>[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-196438&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;&#8221; text_weight=&#8221;600&#8243; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;980426&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00ceNTREB\u0102RILE DUMNEAVOASTR\u0102, CU R\u0102SPUNS.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;1&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;100&#8243; back_color=&#8221;color-138503&#8243; back_image=&#8221;112249&#8243; back_repeat=&#8221;no-repeat&#8221; back_attachment=&#8221;fixed&#8221; back_position=&#8221;center bottom&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; enable_bottom_divider=&#8221;default&#8221; bottom_divider_inv=&#8221;tilt&#8221; shape_bottom_invert=&#8221;yes&#8221; shape_bottom_h_use_pixel=&#8221;&#8221; shape_bottom_height=&#8221;100&#8243; shape_bottom_color=&#8221;color-xsdn&#8221; shape_bottom_opacity=&#8221;100&#8243; shape_bottom_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; mobile_visibility=&#8221;yes&#8221; row_name=&#8221;iphone&#8221; el_class=&#8221;gradient&#8221; uncode_shortcode_id=&#8221;114217&#8243; back_color_type=&#8221;uncode-palette&#8221; shape_bottom_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;7&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; animation_delay=&#8221;200&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;276875&#8243; column_width_pixel=&#8221;1000&#8243;][vc_empty_space empty_h=&#8221;3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; heading_semantic=&#8221;h1&#8243; text_font=&#8221;font-514338&#8243; text_weight=&#8221;300&#8243; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;166716&#8243; text_color_type=&#8221;uncode-palette&#8221;]<span style=\"font-weight: 400;\">\u00centreb\u0103ri frecvente<\/span>[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-196438&#8243; heading_semantic=&#8221;h1&#8243; text_font=&#8221;font-195745&#8243; text_size=&#8221;&#8221; text_weight=&#8221;600&#8243; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;105352&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00ceNTREB\u0102RILE DUMNEAVOASTR\u0102, CU R\u0102SPUNS.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;1&#8243;][vc_empty_space empty_h=&#8221;5&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;100&#8243; back_color=&#8221;color-138503&#8243; back_image=&#8221;112248&#8243; back_attachment=&#8221;scroll&#8221; back_position=&#8221;center center&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; enable_bottom_divider=&#8221;default&#8221; bottom_divider_inv=&#8221;tilt&#8221; shape_bottom_invert=&#8221;yes&#8221; shape_bottom_h_use_pixel=&#8221;&#8221; shape_bottom_height=&#8221;100&#8243; shape_bottom_color=&#8221;color-xsdn&#8221; shape_bottom_opacity=&#8221;100&#8243; shape_bottom_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; row_name=&#8221;iphone&#8221; el_class=&#8221;gradient&#8221; uncode_shortcode_id=&#8221;308018&#8243; back_color_type=&#8221;uncode-palette&#8221; shape_bottom_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;7&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; css_animation=&#8221;bottom-t-top&#8221; animation_delay=&#8221;200&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;276875&#8243; column_width_pixel=&#8221;1000&#8243;][vc_empty_space empty_h=&#8221;2&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; heading_semantic=&#8221;h1&#8243; text_font=&#8221;font-514338&#8243; text_size=&#8221;h4&#8243; text_weight=&#8221;300&#8243; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;134194&#8243; text_color_type=&#8221;uncode-palette&#8221;]<span style=\"font-weight: 400;\">\u00centreb\u0103ri frecvente<\/span>[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-196438&#8243; heading_semantic=&#8221;h1&#8243; text_font=&#8221;font-195745&#8243; text_weight=&#8221;600&#8243; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;420235&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00ceNTREB\u0102RILE DUMNEAVOASTR\u0102, CU R\u0102SPUNS.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;5&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;7&#8243; bottom_padding=&#8221;7&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;0&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; top_divider=&#8221;step_1_2&#8243; desktop_visibility=&#8221;yes&#8221; mobile_visibility=&#8221;yes&#8221; changer_back_color=&#8221;yes&#8221; uncode_shortcode_id=&#8221;120331&#8243; back_color_type=&#8221;uncode-palette&#8221; row_name=&#8221;questions&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;5&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;166430&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;384218&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00centreb\u0103ri generale[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;999729&#8243; subheading=&#8221;Starea dumneavoastr\u0103 de s\u0103n\u0103tate va fi monitorizat\u0103 cu aten\u021bie pe \u00eentreaga durat\u0103 a studiului StrateGIST 3. Chiar dac\u0103 nu ob\u021bine\u021bi beneficii directe din participarea la studiu, eventualele informa\u021bii colectate \u00eei pot ajuta pe cercet\u0103tori s\u0103 afle mai multe despre medicamentul de studiu IDRX-42 \u0219i despre tratarea altor adul\u021bi cu GIST \u00een viitor.&#8221;]Care sunt beneficiile particip\u0103rii la StrateGIST 3?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;146860&#8243; subheading=&#8221;Ca \u00een cazul tuturor medicamentelor, exist\u0103 un risc de apari\u021bie a reac\u021biilor adverse din cauza medicamentelor de studiu. Cu toate acestea, siguran\u021ba dumneavoastr\u0103 este prioritatea noastr\u0103. Starea dumneavoastr\u0103 de s\u0103n\u0103tate va fi monitorizat\u0103 cu aten\u021bie pe \u00eentreaga durat\u0103 a studiului. Un grup special de exper\u021bi, denumit Comisia de monitorizare a datelor va analiza, de asemenea, datele pe tot parcursul desf\u0103\u0219ur\u0103rii studiului, pentru a se asigura c\u0103 participan\u021bii r\u0103m\u00e2n \u00een siguran\u021b\u0103.&#8221;]Exist\u0103 riscuri privind participarea la studiu?[\/vc_custom_heading][vc_custom_heading 1=&#8221;biopharmaceutical&#8221; 2=&#8221;company&#8221; 3=&#8221;IDRx,&#8221; 4=&#8221;Inc.&#8221; 5=&#8221;is&#8221; 6=&#8221;sponsoring&#8221; 7=&#8221;the&#8221; 8=&#8221;clinical&#8221; 9=&#8221;trial.&#8221; 10=&#8221;They&#8221; 11=&#8221;will&#8221; 12=&#8221;pay&#8221; 13=&#8221;the&#8221; 14=&#8221;study&#8221; 15=&#8221;doctor&#8221; 16=&#8221;and&#8221; 17=&#8221;site&#8221; 18=&#8221;staff&#8221; 19=&#8221;to&#8221; 20=&#8221;run&#8221; 21=&#8221;this&#8221; 22=&#8221;trial.&#8221; 23=&#8221;To&#8221; 24=&#8221;learn&#8221; 25=&#8221;more&#8221; 26=&#8221;about&#8221; 27=&#8221;IDRx,&#8221; 28=&#8221;visit&#8221; 29=&#8221;&#8221; 30=&#8221;href=&#8222;&#8222;https:\/\/www.idrx.com&#8222;&#8222;&gt;www.idrx.com&#8221; 31=&#8221;.&#8222;&#8221; heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;148716&#8243;]Cine sponsorizeaz\u0103 studiul clinic StrateGIST 3?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;203685&#8243; css=&#8221;.vc_custom_1731516055759{margin-top: 10px !important;}&#8221;]<span style=\"font-weight: 400;\">Compania biofarmaceutic\u0103 IDRx, Inc. sponsorizeaz\u0103 studiul clinic StrateGIST 3. Aceasta va remunera medicii de studiu \u0219i personalul de la centru pentru a desf\u0103\u0219ura studiul. Pentru a afla mai multe despre IDRx, vizita\u021bi <\/span><a href=\"https:\/\/www.idrx.com\/\" target=\"_blank\" rel=\"noopener\">www.idrx.com<\/a>.[\/vc_column_text][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;150124&#8243; subheading=&#8221;Tratamentul de studiu, vizitele la centru \u0219i testele asociate studiului vor fi pl\u0103tite de sponsorul studiului clinic, IDRx, Inc. \u0219i vor fi gratuite pentru dumneavoastr\u0103. Vi se vor rambursa cheltuielile rezonabile pentru deplas\u0103rile asociate vizitelor de studiu.&#8221;]Participarea la studiu va presupune vreun cost pentru mine?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;430406&#8243; subheading=&#8221;Participarea la un studiu clinic este voluntar\u0103. Dac\u0103 decide\u021bi s\u0103 participa\u021bi \u0219i ulterior v\u0103 r\u0103zg\u00e2ndi\u021bi, pute\u021bi p\u0103r\u0103si studiul \u00een orice moment. Retragerea din studiu nu va afecta \u00eengrijirea dumneavoastr\u0103 medical\u0103 de rutin\u0103.&#8221;]Ce se \u00eent\u00e2mpl\u0103 dac\u0103 decid s\u0103 particip la studiu \u0219i apoi m\u0103 r\u0103zg\u00e2ndesc?[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;115706&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00centreb\u0103ri privind medicamentul de studiu[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;138330&#8243; subheading=&#8221;GIST sunt cauzate frecvente de modific\u0103ri sau muta\u021bii ale unei gene care produce o protein\u0103 celular\u0103 normal\u0103, denumit\u0103 KIT. Aceste muta\u021bii duc la supraactivarea KIT &#8211; precum un comutator blocat \u00een pozi\u021bie &#8211; cauz\u00e2nd multiplicarea celulelor canceroase.<\/p>\n<p>IDRX-42 este un inhibitor al tirozin-kinazei (TKI). TKI opresc sau \u00eencetinesc activitatea KIT \u0219i cre\u0219terea rezultat\u0103 a celulelor canceroase. Alte TKI sunt utilizate pentru GIST, \u00eens\u0103 este posibil s\u0103 nu func\u021bioneze \u00eempotriva tuturor muta\u021biilor <i>KIT<\/i>. IDRX-42 este conceput s\u0103 acopere un spectru mai larg de muta\u021bii <i>KIT<\/i>.&#8221; text_color_type=&#8221;uncode-palette&#8221; text_color_solid=&#8221;#ff0000&#8243;]Ce este IDRX-42?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;172011&#8243; subheading=&#8221;Ca \u00een cazul tuturor medicamentelor, exist\u0103 posibilitatea de apari\u021bie a reac\u021biilor adverse, care sunt efecte nedorite \u0219i neinten\u021bionate ale unui medicament. Pentru informa\u021bii suplimentare despre posibilele reac\u021bii adverse, discuta\u021bi cu medicul de studiu. Starea dumneavoastr\u0103 de s\u0103n\u0103tate va fi monitorizat\u0103 cu aten\u021bie pe parcursul \u00eentregului studiu. Informa\u021bi-l pe medicul de studiu \u00een cazul \u00een care observa\u021bi orice reac\u021bii adverse sau modific\u0103ri ale st\u0103rii dumneavoastr\u0103 de s\u0103n\u0103tate.&#8221;]Exist\u0103 reac\u021bii adverse asociate cu medicamentele de studiu?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;114741&#8243; subheading=&#8221;Da, medicul de studiu v\u0103 va informa ce tratament de studiu primi\u021bi.<\/p>\n<p>Dac\u0103 sunt repartizat(\u0103) s\u0103 primesc sunitinib, voi avea \u0219ansa s\u0103 primesc IDRX-42? Dac\u0103 lua\u021bi sunitinib \u0219i cancerul dumneavoastr\u0103 se agraveaz\u0103, ve\u021bi putea schimba tratamentul cu IDRX-42.&#8221; text_color_type=&#8221;uncode-palette&#8221; text_color_solid=&#8221;#ff0000&#8243;]Voi \u0219ti dac\u0103 primesc IDRX-42 sau sunitinib?[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;123134&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00centreb\u0103ri privind StrateGIST 3[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;699296&#8243; subheading=&#8221;Ve\u021bi participa la acest studiu timp de p\u00e2n\u0103 la 5,5 ani. La fel ca \u00een cazul tuturor studiilor clinice, pute\u021bi opri participarea \u00een orice moment, din orice motiv sau f\u0103r\u0103 niciun motiv. IDRX, Inc. nu are niciun plan de a v\u0103 furniza IDRX-42 sau orice alte medicamente de studiu sau proceduri dup\u0103 finalul studiului sau dac\u0103 a\u021bi \u00eentrerupt studiul sau a\u021bi fost retras(\u0103) din studiu.&#8221;]C\u00e2t va dura participarea mea la studiu?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;127156&#8243; subheading=&#8221;Dac\u0103 v\u0103 califica\u021bi pentru studiu, ve\u021bi fi repartizat(\u0103) aleatoriu \u00eentr-un grup, pentru a vi se administra fie IDRX-42, fie sunitinib, un tratament aprobat \u00een unele \u021b\u0103ri pentru tipul de GIST studiat.&#8221;]Ce tratament de studiu mi se va administra?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;514493&#8243; subheading=&#8221;IDRX-42 este furnizat sub form\u0103 de comprimate pe care le ve\u021bi lua pe cale oral\u0103 cu ap\u0103 (cu sau f\u0103r\u0103 alimente). Ve\u021bi lua IDRX-42 o dat\u0103 pe zi, conform instruc\u021biunilor medicului de studiu. Ve\u021bi continua s\u0103 lua\u021bi IDRX-42 at\u00e2t timp c\u00e2t cancerul dumneavoastr\u0103 nu se agraveaz\u0103 \u0219i dumneavoastr\u0103 tolera\u021bi tratamentul.&#8221;]Cum administrez IDRX-42?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;355188&#8243; subheading=&#8221;Sunitinib este furnizat sub form\u0103 de capsule pe care le ve\u021bi lua pe cale oral\u0103 cu ap\u0103 (cu sau f\u0103r\u0103 alimente). Sunitinibul se administreaz\u0103 o dat\u0103 pe zi timp de 28 de zile consecutive, urmate de o pauz\u0103 de 14 zile, cu excep\u021bia cazului \u00een care sunte\u021bi instruit(\u0103) altfel. Ve\u021bi continua s\u0103 lua\u021bi sunitinib at\u00e2t timp c\u00e2t cancerul dumneavoastr\u0103 nu se agraveaz\u0103 \u0219i dumneavoastr\u0103 tolera\u021bi tratamentul. \u00cen cazul \u00een care cancerul dumneavoastr\u0103 se agraveaz\u0103 \u00een timpul tratamentului cu sunitinib, ve\u021bi putea schimba tratamentul cu IDRX-42.&#8221;]Cum administrez sunitinib?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;700478&#8243;]Care sunt centrele de studiu clinic care particip\u0103 la StrateGIST 3?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;480045&#8243; css=&#8221;.vc_custom_1732655988927{margin-top: 10px !important;}&#8221;]Face\u021bi clic <a href=\"\/#location\">aici<\/a> pentru o list\u0103 a centrelor participante \u0219i pentru a g\u0103si o loca\u021bie \u00een apropierea dumneavoastr\u0103.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;7&#8243; bottom_padding=&#8221;7&#8243; back_color=&#8221;color-xsdn&#8221; back_image=&#8221;112276&#8243; back_attachment=&#8221;fixed&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;0&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; top_divider=&#8221;step_1_2&#8243; medium_visibility=&#8221;yes&#8221; changer_back_color=&#8221;yes&#8221; uncode_shortcode_id=&#8221;111832&#8243; back_color_type=&#8221;uncode-palette&#8221; row_name=&#8221;questions&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;5&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;166430&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;384218&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00centreb\u0103ri generale[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;204481&#8243; subheading=&#8221;Nu sunt garantate beneficii, cu toate acestea, starea dumneavoastr\u0103 de s\u0103n\u0103tate va fi monitorizat\u0103 cu aten\u021bie pe \u00eentreaga durat\u0103 a studiului StrateGIST 3. Chiar dac\u0103 nu ob\u021bine\u021bi beneficii directe din participarea la studiu, eventualele informa\u021bii colectate \u00eei pot ajuta pe cercet\u0103tori s\u0103 afle mai multe despre medicamentul de studiu IDRX-42 (GSK6042981) \u0219i despre tratarea altor adul\u021bi cu GIST \u00een viitor.&#8221;]Care sunt beneficiile particip\u0103rii la StrateGIST 3?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;104022&#8243; subheading=&#8221;Ca \u00een cazul tuturor medicamentelor, exist\u0103 un risc de apari\u021bie a reac\u021biilor adverse din cauza medicamentelor de studiu. Cu toate acestea, siguran\u021ba dumneavoastr\u0103 este prioritatea noastr\u0103. Starea dumneavoastr\u0103 de s\u0103n\u0103tate va fi monitorizat\u0103 cu aten\u021bie pe \u00eentreaga durat\u0103 a studiului.&#8221;]Exist\u0103 riscuri privind participarea la studiu?[\/vc_custom_heading][vc_custom_heading 1=&#8221;biopharmaceutical&#8221; 2=&#8221;company&#8221; 3=&#8221;IDRx,&#8221; 4=&#8221;Inc.&#8221; 5=&#8221;is&#8221; 6=&#8221;sponsoring&#8221; 7=&#8221;the&#8221; 8=&#8221;clinical&#8221; 9=&#8221;trial.&#8221; 10=&#8221;They&#8221; 11=&#8221;will&#8221; 12=&#8221;pay&#8221; 13=&#8221;the&#8221; 14=&#8221;study&#8221; 15=&#8221;doctor&#8221; 16=&#8221;and&#8221; 17=&#8221;site&#8221; 18=&#8221;staff&#8221; 19=&#8221;to&#8221; 20=&#8221;run&#8221; 21=&#8221;this&#8221; 22=&#8221;trial.&#8221; 23=&#8221;To&#8221; 24=&#8221;learn&#8221; 25=&#8221;more&#8221; 26=&#8221;about&#8221; 27=&#8221;IDRx,&#8221; 28=&#8221;visit&#8221; 29=&#8221;&#8221; 30=&#8221;href=&#8222;&#8222;https:\/\/www.idrx.com&#8222;&#8222;&gt;www.idrx.com&#8221; 31=&#8221;.&#8222;&#8221; heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;657637&#8243;]Cine sponsorizeaz\u0103 studiul clinic StrateGIST 3?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;779402&#8243; css=&#8221;.vc_custom_1755617742215{margin-top: 10px !important;}&#8221;]<span style=\"font-weight: 400;\">Compania biofarmaceutic\u0103 global\u0103 GSK sponsorizeaz\u0103 studiul clinic StrateGIST 3. Aceasta va remunera medicii de studiu \u0219i personalul de la centru pentru a desf\u0103\u0219ura studiul. Pentru a afla mai multe despre GSK, vizita\u021bi <\/span><a href=\"https:\/\/us.gsk.com\/en-us\/\" target=\"_blank\" rel=\"noopener\">www.gsk.com<\/a>.[\/vc_column_text][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;116327&#8243; subheading=&#8221;Tratamentul de studiu, vizitele la centru \u0219i testele asociate studiului vor fi pl\u0103tite de sponsorul studiului clinic, GSK \u0219i vor fi gratuite pentru dumneavoastr\u0103. Vi se pot rambursa cheltuielile rezonabile pentru deplas\u0103rile asociate vizitelor de studiu.&#8221;]Participarea la studiu va presupune vreun cost pentru mine?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;430406&#8243; subheading=&#8221;Participarea la un studiu clinic este voluntar\u0103. Dac\u0103 decide\u021bi s\u0103 participa\u021bi \u0219i ulterior v\u0103 r\u0103zg\u00e2ndi\u021bi, pute\u021bi p\u0103r\u0103si studiul \u00een orice moment. Retragerea din studiu nu va afecta \u00eengrijirea dumneavoastr\u0103 medical\u0103 de rutin\u0103.&#8221;]Ce se \u00eent\u00e2mpl\u0103 dac\u0103 decid s\u0103 particip la studiu \u0219i apoi m\u0103 r\u0103zg\u00e2ndesc?[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;115706&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00centreb\u0103ri privind medicamentul de studiu[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;159505&#8243; subheading=&#8221;GIST sunt cauzate frecvente de modific\u0103ri sau muta\u021bii ale unei gene care produce o protein\u0103 celular\u0103 normal\u0103, denumit\u0103 KIT. Aceste muta\u021bii duc la supraactivarea KIT &#8211; precum un comutator blocat \u00een pozi\u021bie &#8211; cauz\u00e2nd multiplicarea celulelor canceroase.<\/p>\n<p>IDRX-42 (GSK6042981) este un inhibitor al tirozin-kinazei (TKI). TKI opresc sau \u00eencetinesc activitatea KIT \u0219i cre\u0219terea rezultat\u0103 a celulelor canceroase. Alte TKI sunt utilizate pentru GIST, \u00eens\u0103 este posibil s\u0103 nu func\u021bioneze \u00eempotriva tuturor muta\u021biilor KIT. IDRX-42 (GSK6042981) este conceput s\u0103 acopere un spectru mai larg de muta\u021bii KIT.&#8221; text_color_type=&#8221;uncode-palette&#8221; text_color_solid=&#8221;#ff0000&#8243;]Ce este IDRX-42 (GSK6042981)[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;172011&#8243; subheading=&#8221;Ca \u00een cazul tuturor medicamentelor, exist\u0103 posibilitatea de apari\u021bie a reac\u021biilor adverse, care sunt efecte nedorite \u0219i neinten\u021bionate ale unui medicament. Pentru informa\u021bii suplimentare despre posibilele reac\u021bii adverse, discuta\u021bi cu medicul de studiu. Starea dumneavoastr\u0103 de s\u0103n\u0103tate va fi monitorizat\u0103 cu aten\u021bie pe parcursul \u00eentregului studiu. Informa\u021bi-l pe medicul de studiu \u00een cazul \u00een care observa\u021bi orice reac\u021bii adverse sau modific\u0103ri ale st\u0103rii dumneavoastr\u0103 de s\u0103n\u0103tate.&#8221;]Exist\u0103 reac\u021bii adverse asociate cu medicamentele de studiu?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;970928&#8243; subheading=&#8221;Da, medicul de studiu v\u0103 va informa ce tratament de studiu primi\u021bi.&#8221;]Voi \u0219ti dac\u0103 primesc IDRX-42 (GSK6042981)<br \/>\nsau sunitinib?[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner width=&#8221;1\/3&#8243;][vc_custom_heading text_color=&#8221;color-681992&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;123134&#8243; text_color_type=&#8221;uncode-palette&#8221;]\u00centreb\u0103ri privind StrateGIST 3[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;759072&#8243; subheading=&#8221;Ve\u021bi participa la acest studiu timp de p\u00e2n\u0103 la 5 ani. La fel ca \u00een cazul tuturor studiilor clinice, pute\u021bi opri participarea \u00een orice moment, din orice motiv sau f\u0103r\u0103 niciun motiv. GSK nu are niciun plan de a v\u0103 furniza IDRX-42 (GSK6042981) sau orice alte medicamente de studiu sau proceduri dup\u0103 finalul studiului sau dac\u0103 a\u021bi \u00eentrerupt studiul sau a\u021bi fost retras(\u0103) din studiu.&#8221;]C\u00e2t va dura participarea mea la studiu?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;124602&#8243; subheading=&#8221;Dac\u0103 v\u0103 califica\u021bi pentru studiu, ve\u021bi fi repartizat(\u0103) aleatoriu \u00eentr-un grup, pentru a vi se administra fie IDRX-42 (GSK6042981), fie sunitinib, un tratament aprobat \u00een unele \u021b\u0103ri pentru tipul de GIST studiat. La finalul studiului, dac\u0103 v\u0103 califica\u021bi, GSK v\u0103 poate furniza acces la IDRX-42 (GSK6042981) prin intermediul unui program de acces separat, \u00een func\u021bie de reglement\u0103rile locale.&#8221;]Ce tratament de studiu mi se va administra?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;191460&#8243; subheading=&#8221;IDRX-42 (GSK6042981) este furnizat sub form\u0103 de comprimate pe care le ve\u021bi lua pe cale oral\u0103 cu ap\u0103 (cu sau f\u0103r\u0103 alimente). Ve\u021bi lua IDRX-42 (GSK6042981) o dat\u0103 pe zi, conform instruc\u021biunilor medicului de studiu. Ve\u021bi continua s\u0103 lua\u021bi IDRX-42 (GSK6042981) at\u00e2t timp c\u00e2t cancerul dumneavoastr\u0103 nu se agraveaz\u0103 \u0219i dumneavoastr\u0103 tolera\u021bi tratamentul.&#8221;]Cum administrez IDRX-42 (GSK6042981)?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;152983&#8243; subheading=&#8221;Sunitinib este furnizat sub form\u0103 de capsule pe care le ve\u021bi lua pe cale oral\u0103 cu ap\u0103 (cu sau f\u0103r\u0103 alimente). Sunitinibul se administreaz\u0103 o dat\u0103 pe zi timp de 28 de zile consecutive, urmate de o pauz\u0103 de 14 zile, cu excep\u021bia cazului \u00een care sunte\u021bi instruit(\u0103) altfel. Ve\u021bi continua s\u0103 lua\u021bi sunitinib at\u00e2t timp c\u00e2t cancerul dumneavoastr\u0103 nu se agraveaz\u0103 \u0219i dumneavoastr\u0103 tolera\u021bi tratamentul.&#8221;]Cum administrez sunitinib?[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;h3&#8243; text_size=&#8221;&#8221; sub_reduced=&#8221;yes&#8221; text_align=&#8221;text-left&#8221; text_serif=&#8221;yes&#8221; uncode_shortcode_id=&#8221;700478&#8243;]Care sunt centrele de studiu clinic care particip\u0103 la StrateGIST 3?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=&#8221;480045&#8243; css=&#8221;.vc_custom_1732655988927{margin-top: 10px !important;}&#8221;]Face\u021bi clic <a href=\"\/#location\">aici<\/a> pentru o list\u0103 a centrelor participante \u0219i pentru a g\u0103si o loca\u021bie \u00een apropierea dumneavoastr\u0103.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;100&#8243; back_color=&#8221;color-138503&#8243; back_image=&#8221;112255&#8243; back_repeat=&#8221;no-repeat&#8221; back_attachment=&#8221;scroll&#8221; back_position=&#8221;center center&#8221; parallax=&#8221;yes&#8221; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; enable_bottom_divider=&#8221;default&#8221; bottom_divider_inv=&#8221;tilt&#8221; shape_bottom_invert=&#8221;yes&#8221; shape_bottom_h_use_pixel=&#8221;&#8221; shape_bottom_height=&#8221;100&#8243; shape_bottom_color=&#8221;color-xsdn&#8221; [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-138784","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/pages\/138784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/comments?post=138784"}],"version-history":[{"count":0,"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/pages\/138784\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg.strategist3trial.com\/ro\/wp-json\/wp\/v2\/media?parent=138784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}